CompletedPhase 3NCT04556656
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Studying Huntington disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Prilenia
- Principal Investigator
- Yael CohenPrilenia
- Intervention
- Pridopidine(drug)
- Enrollment
- 499 enrolled
- Eligibility
- 25 years · All sexes
- Timeline
- 2020 – 2024
Study locations (30)
- Prilenia Investigational Site (Site 061), Davis, California, United States
- Prilenia Investigational Site (Site 051), San Diego, California, United States
- Prilenia Investigational Site (Site 343), Englewood, Colorado, United States
- Prilenia Investigational Site (Site 333), Washington D.C., District of Columbia, United States
- Prilenia Investigational Site (Site 160), Gainesville, Florida, United States
- Prilenia Investigational Site (Site 019), Tampa, Florida, United States
- Prilenia Investigational Site (Site 032), Atlanta, Georgia, United States
- Prilenia Investigational Site (Site 088), Chicago, Illinois, United States
- Prilenia Investigational Site (Site 029), Kansas City, Kansas, United States
- Prilenia Investigational Site (Site 083), Wichita, Kansas, United States
- Prilenia Investigational Site (Site 087), Louisville, Kentucky, United States
- Prilenia Investigational Site (Site 028), Baltimore, Maryland, United States
- Prilenia Investigational Site (Site 017), Boston, Massachusetts, United States
- Prilenia Investigational Site (Site 076), Boston, Massachusetts, United States
- Prilenia Investigational Site (Site 027), St Louis, Missouri, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04556656 on ClinicalTrials.govOther trials for Huntington disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07513844Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's DiseaseFirst Affiliated Hospital of Fujian Medical University
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07537075An Extension of SKY-0515 in Participants With Huntington's DiseaseSkyhawk Therapeutics, Inc.
- RECRUITINGPHASE3NCT07326709A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's DiseaseNovartis Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT07451613Safety and Tolerability Study of Human Neural Stem Cells for Huntington's DiseaseLeslie Thompson
- RECRUITINGEARLY PHASE1NCT06634628iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009CHDI Foundation, Inc.
- RECRUITINGPHASE2, PHASE3NCT07378644Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's DiseaseSkyhawk Therapeutics, Inc.
- RECRUITINGNCT07253038Evaluation of Three Tests to Assess Social Cognition in Huntington DiseaseRegion Skane
- RECRUITINGNANCT07213648Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)University of Virginia